• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Here’s why Hims & Hers stock price has crashed: buy the dip?

by March 27, 2025
by March 27, 2025

Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year. So, why has the telemedicine stock crashed, and what to expect.

Why HIMS stock has plunged

Hims & Hers is a top company that sells healthcare products used by millions of customers in the US. Its strategy is to focus on niche conditions that people have struggled with for years. These conditions include weight loss, hair, anxiety, skin, and sex. Largely, all Americans face at least one of these challenges, giving it a large, addressable market.

The main reason why the Hims stock price has crashed is that its biggest business is under threat. Hims & Hers started offering compounded GLP-1 treatments, which are generic versions of the weight loss products made by companies like Eli Lilly and Novo Nordisk. 

The compounded drugs are effective and much cheaper than those made by large companies. Customers pay about $200 for the drugs sold by Hims, much lower than the $1,000 sold by the larger companies. 

Hims & Hers is also cheaper than other companies in the industry. The average annual cost of its GLP drugs is $1,980, lower than WW’s $2,208, Henry’s $2,864, Noom’s $3,218, and Ro’s $4,583.

Read more: Will the falling Hims & Hers stock price recover in 2025?

The challenge, however, is that Hims & Hers drugs have not been approved by the FDA, which has sued to stop the tirzepatide sales. In a court ruling this month, a judge sided with the FDA, meaning that, in the longer term, Hims could face a challenge. Hims is running adverts and campaigns pressuring the FDA to allow compounding. 

The weight loss division is an important part of Hims business because of its higher margins. Also, unlike other divisions, these customers will remain with the company for a long time. In most cases, stopping to take weight loss products usually leads to more weight gain.

Hims growth has accelerated

The most recent financial results show that Hims & Hers business has surged in the past few quarters, mostly because of its compounded drugs. 

Hims & Hers made over $481 million in the fourth quarter, up by 95% from the same period  year earlier. This led to an annual revenue of $1.5 billion, a 69% annual increase.

The company also made a net profit of $26 million in the fourth quarter and $126 million in the full year. This growth happened as the number of subscribers surged by 45% to 2.2 million. Most of these subscribers are mostly because of its weight loss products. 

Analysts anticipate that this growth will continue in the coming years. The average estimate is that Hims’ revenue will grow by 92% in the first quarter to $535 million and $2.3 billion this year.

Read more: Is the soaring Hims & Hers stock a good investment?

Hims & Hers stock price analysis

HIMS chart by TradingView

The weekly chart shows that the HIMS stock price peaked at $72.9 earlier this year, and has crashed to $33.35. It has remained above the 25-week Exponential Moving Average (EMA), and is above the key support at $25.30 

The HIMS stock has moved inside the ascending channel in the past few weeks. Also, the two lines of the MACD indicator have pointed downwards, while the Relative Strength Index (RSI) have pointed downwards.

Therefore, the stock will likely have a strong bullish breakout when the GLP issue cools in the coming weeks. If this happens, the next key resistance point to watch will be at $50, up by almost 50% from the current level.

The post Here’s why Hims & Hers stock price has crashed: buy the dip? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
20% of South Korean officials hold crypto worth $9.8M
next post
Top 4 vulnerable auto stocks to sell after Trump’s pre-Liberation Day tariffs

Related Posts

Asian markets open: most futures lower; Sensex to...

June 6, 2025

Here’s why the Nifty 50 Index may surge...

June 6, 2025

Circle stock price prediction: is CRCL a good...

June 6, 2025

Trump-Musk fallout risks SpaceX deals, Tesla’s standing, and...

June 6, 2025

European markets open: Stoxx 600 flat ahead of...

June 6, 2025

Musk, Trump dial back feud as White House...

June 6, 2025

XRP slips 2.5% to $2.14 as Trump-Musk clash...

June 6, 2025

China’s May export growth seen slowing to 5.0%...

June 6, 2025

FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo,...

June 6, 2025

Citi downgrades CEG stock despite Constellation Energy’s big...

June 5, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Relative Drug Pricing is Bad Medicine

    June 6, 2025
  • Want to Fix Medicaid? Look to Milton Friedman

    June 6, 2025
  • Want to Fix Medicaid? Look to Milton Friedman

    June 6, 2025
  • Relative Drug Pricing is Bad Medicine

    June 6, 2025
  • Asian markets open: most futures lower; Sensex to open flat as RBI policy decision looms

    June 6, 2025
  • Here’s why the Nifty 50 Index may surge after the RBI rate cut

    June 6, 2025

Editors’ Picks

  • 1

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 2

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025

Categories

  • Economy (1,373)
  • Editor's Pick (143)
  • Investing (165)
  • Stock (882)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

How Hermès stays resilient in economic uncertainty...

April 21, 2025

Auto giant Toyota forges alliance with Waymo...

April 30, 2025

Bezos to sell up to $4.75B in...

May 3, 2025